State-of-the-art of minimally invasive treatments of bone metastases

Li, Cun; Wu, Qianghua; Chang, Daijun; Liang, Hui; Ding, Xiaofei; Lao, Chendeng; Huang, Zonggui

doi:10.1016/j.jbo.2022.100425

Cited by 5 publications

(4 citation statements)

References 115 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Calmels et al performed PVP in 52 patients with 53 osteoblastic metastases and 50 mixed spinal metastases; the rate of pain relief at 1 and 6 months after surgery was 86% and 92%, respectively, while the rate of cement leakage was 50.5% (52/103) [ 21 ]. Microwave ablation uses the microwave magnetic field released by the MWA needle to rotate the polar molecules and charged particles around at high speed, which causes tissue solidification, dehydration, and necrosis through friction heating [ 22 ]. Theoretically, MWA can achieve better tissue penetration than other types of thermal energy in the treatment of bone metastases owing to the low electrical conductivity of bone tissue [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…Theoretically, MWA can achieve better tissue penetration than other types of thermal energy in the treatment of bone metastases owing to the low electrical conductivity of bone tissue [ 23 ]. Compared with radiofrequency ablation, MWA has the characteristics of high ablation frequency, strong penetration, and multi-needle joint ablation; therefore, MWA has faster thermogenesis, higher temperature in the tumor, shorter ablation time, and larger ablation area [ 22 ]. Radiofrequency ablation is reportedly not suitable for osteogenic metastases because the electrode needle is difficult to open in osteogenic lesions [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Microwave ablation combined with vertebral augmentation under real-time temperature monitoring for the treatment of painful spinal osteogenic metastases

Fan

Zhang

et al. 2023

BMC Neurol

View full text Add to dashboard Cite

Objective To evaluate the safety and efficacy of computed tomography (CT)-guided microwave ablation combined with vertebral augmentation under real-time temperature monitoring in the treatment of painful osteogenic spinal metastases. Methods This retrospective study included 38 patients with 63 osteogenic metastatic spinal lesions treated using CT-guided microwave ablation and vertebral augmentation under real-time temperature monitoring. Visual analog scale scores, daily morphine consumption, and Oswestry Disability Index scores were used to evaluate efficacy of the treatment. Results Microwave ablation combined with vertebral augmentation reduced the mean visual analog scale scores from 6.40 ± 1.90 preoperatively to 3.32 ± 0.96 at 24 h, 2.24 ± 0.91 at 1 week, 1.92 ± 1.32 at 4 weeks, 1.79 ± 1.45 at 12 weeks, and 1.39 ± 1.12 at 24 weeks postoperatively (all p < 0.001). The mean preoperative daily morphine consumption was 108.95 ± 56.41 mg, which decreased to 50.13 ± 25.46 mg at 24 h, 31.18 ± 18.58 mg at 1 week, 22.50 ± 16.63 mg at 4 weeks, 21.71 ± 17.68 mg at 12 weeks, and 17.27 ± 16.82 mg at 24 weeks postoperatively (all p < 0.001). During the follow-up period, the Oswestry Disability Index scores significantly reduced (p < 0.001). Bone cement leakage occurred in 25 vertebral bodies, with an incidence of 39.7% (25/63). Conclusions The results indicate that microwave ablation combined with vertebral augmentation under real-time temperature monitoring is a feasible, effective, and safe treatment for painful osteoblast spinal metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Microwave ablation combined with vertebral augmentation under real-time temperature monitoring for the treatment of painful spinal osteogenic metastases

Fan

Zhang

et al. 2023

BMC Neurol

View full text Add to dashboard Cite

show abstract

“…According to the existing epidemiological data, bone metastases can appear in many types of malignant tumors, especially breast cancer, lung cancer, prostate cancer, kidney cancer and thyroid cancer ( 6 ). Bone metastases have been reported in 40% of non-small cell lung cancer ( 7 ).…”

Section: Epidemiological Pathological and Clinical Features Of Bone M...mentioning

confidence: 99%

Research progress of bone metastases: From disease recognition to clinical practice

Yang

Huang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Bone metastases, as one of the common types of metastatic tumors, have a great impact on the survival period and quality of life of patients. Bone metastases are usually characterized by bone destruction. Skeletal related events caused by bone destruction often lead to pain, pathological fractures and even paralysis. In this review, we provide a detailed explanation of bone metastases from the epidemiology, clinical features, pathogenesis, and recently developed clinical treatment viewpoints. We concluded that the incidence of bone metastases is increasing gradually, with serious clinical symptoms, complex pathogenesis and diverse clinical treatment. Tumor cells, immune cells, osteoblasts/osteoclasts and other cells as well as cytokines and enzymes all play a key role in the pathogenesis of bone metastases. We believe that the future treatment of bone metastases will be diversified and comprehensive. Some advanced technologies, such as nanomedicine, could be used for treatment, but this depends on understanding how disease occurs. With the development of treatment, the survival time and quality of life of patients will be improved.

show abstract

“… 3 In particular, 70% of patients with breast and prostate cancers develop bone metastases. 4 Cancer-induced bone pain (CIBP) is a serious complication of bone metastases, with up to 85% of patients experiencing high intensity pain that is commonly crippling, persistent, spontaneous, usually accompanied by hyperalgesia, and diminishing the quality of life (QoL). 5 The pathophysiology underlying CIBP is complex and multifactorial, and it is mainly associated with traumatic, neuropathic processes, and inflammatory pain, but the mechanisms remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Esketamine inhibits the c-Jun N-terminal kinase pathway in the spinal dorsal horn to relieve bone cancer pain in rats

Duan,

Zhu,

Zhang

et al. 2024

Mol Pain

View full text Add to dashboard Cite

Cancer-induced bone pain (CIBP) is one of the most common and feared symptoms in patients with advanced tumors. The X-C motif chemokine ligand 12 (CXCL12) and the CXCR4 receptor have been associated with glial cell activation in bone cancer pain. Moreover, mitogen-activated protein kinases (MAPKs), as downstream CXCL12/CXCR4 signals, and c-Jun, as activator protein AP-1 components, contribute to the development of various types of pain. However, the specific CIBP mechanisms remain unknown. Esketamine is a non-selective N-methyl-d-aspartic acid receptor (NMDA) inhibitor commonly used as an analgesic in the clinic, but its analgesic mechanism in bone cancer pain remains unclear. We used a tumor cell implantation (TCI) model and explored that CXCL12/CXCR4, p-MAPKs, and p-c-Jun were stably up-regulated in the spinal cord. Immunofluorescence images showed activated microglia in the spinal cord on day 14 after TCI and co-expression of CXCL12/CXCR4, p-MAPKs (p-JNK, p-ERK, p-p38 MAPK), and p-c-Jun in microglia. Intrathecal injection of the CXCR4 inhibitor AMD3100 reduced JNK and c-Jun phosphorylations, and intrathecal injection of the JNK inhibitor SP600125 and esketamine also alleviated TCI-induced pain and reduced the expression of p-JNK and p-c-Jun in microglia. Overall, our data suggest that the CXCL12/CXCR4-JNK-c-Jun signaling pathway of microglia in the spinal cord mediates neuronal sensitization and pain hypersensitivity in cancer-induced bone pain and that esketamine exerts its analgesic effect by inhibiting the JNK-c-Jun pathway.

show abstract

State-of-the-art of minimally invasive treatments of bone metastases

Cited by 5 publications

References 115 publications

Microwave ablation combined with vertebral augmentation under real-time temperature monitoring for the treatment of painful spinal osteogenic metastases

Microwave ablation combined with vertebral augmentation under real-time temperature monitoring for the treatment of painful spinal osteogenic metastases

Research progress of bone metastases: From disease recognition to clinical practice

Esketamine inhibits the c-Jun N-terminal kinase pathway in the spinal dorsal horn to relieve bone cancer pain in rats

Contact Info

Product

Resources

About